2‐year survival · 1088 patients with early HCC
1 finding from 1 review
Event‐free survival · 1088 patients with early HCC
1 finding from 1 review
All‐cause mortality · people with liver metastases
It is very uncertain whether microwave coagulation changes all‐cause mortality compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Time to mortality (overall survival) · people with liver metastases
It is very uncertain whether microwave coagulation changes time to mortality (overall survival) compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any adverse events or complications · people with liver metastases
It is very uncertain whether microwave coagulation changes any adverse events or complications compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Disease-free survival · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to clear liver metastases · people with liver metastases
1 finding from 1 review
Recurrence of liver metastases local progression · people with liver metastases
It is very uncertain whether microwave coagulation changes recurrence of liver metastases local progression compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Recurrence of liver metastases distant recurrence · people with liver metastases
It is very uncertain whether microwave coagulation changes recurrence of liver metastases distant recurrence compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Quality of life · heavy menstrual bleeding
1 finding from 1 review
Adverse events · heavy menstrual bleeding
LNG‐IUS probably leads to higher adverse events compared with endometrial ablation (moderate certainty).
1 finding from 1 review
Treatment failure · heavy menstrual bleeding
LNG‐IUS may leads to higher treatment failure compared with endometrial ablation (low certainty).
1 finding from 1 review
Costs · heavy menstrual bleeding
1 finding from 1 review
Bleeding · heavy menstrual bleeding
1 finding from 1 review
Satisfaction with treatment · heavy menstrual bleeding
LNG‐IUS showed no clear difference in satisfaction with treatment compared with endometrial ablation (low certainty).
1 finding from 1 review
All‐cause mortality at last · people with liver metastases
It is very uncertain whether percutaneous ethanol injection changes mortality at last compared with no intervention, other ablation methods, or systemic treatment (very low certainty).
1 finding from 1 review
Time to mortality · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to clear liver metastases or recurrence of liver metastases · people with liver metastases
It is very uncertain whether percutaneous ethanol injection changes failure to clear liver metastases or recurrence of liver metastases compared with no intervention, other ablation methods, or systemic treatment (very low certainty).
1 finding from 1 review